TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03483350
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ampoule
Study: NCT01050764
Drug: Regulatory T-cells
Normalized name: Allogeneic Umbilical Cord Blood Derived Regulatory T-Cells
DrugBank: CK0802 (DB15866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~* T-reg: 1 x 10e5/kg~* T-con: 3 x10e5/kg~Cohort 2~* T-reg: 3 x 10e5/kg~* T-con: 1 x 10e6/kg~Cohort 3~* T-reg: 1 x 10e6/kg~* T-con: 3 x 10e6/kg~Cohort 4~* T-reg: 3 x 10e6/kg~* T-con: 1 x 10e7/kg
Study: NCT01050764
Drug: Conventional T-cells
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
Study: NCT01050764
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
Study: NCT01050764
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
Study: NCT03814200
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single i.v. infusion of 100 mL saline 0.9% for 30 min
Study: NCT01050764
Drug: Anti-thymocyte globulin, rabbit
Normalized name: anti-thymocyte globulin, rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
Study: NCT01050764
Drug: CliniMACS CD34 Reagent System
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
Study: NCT00409942
Drug: Torasemide Prolonged Release
Normalized name: torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
Study: NCT00409942
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
Study: NCT02670785
Drug: Estradiol Vaginal Capsule (EVC)
Normalized name: estradiol Vaginal Cream
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
Study: NCT03814200
Drug: ACT-246475
Normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
Study: NCT00448227
Drug: famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally as a single individualized dose between 25-200 mg based on body weight.
Study: NCT01201694
Drug: Surface-Controlled Water Soluble Curcumin
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 100 mg by mouth two times a day of a 28 day cycle.
Study: NCT01201694
Drug: Surface-Controlled Water Soluble Curcumin MTD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose will be maximum tolerated dose (MTD) from Arm 1.
Study: NCT00277030
Drug: Surfactant
Normalized name: Surfactant
DrugBank: Recombinant surfactant protein D (DB18438)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03814200
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
Study: NCT04394130
Drug: ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
Study: NCT00732745
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00732745
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00732745
Drug: vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT04905667
Drug: GB221
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 mg/kg, single dose, intravenous infusion, 90-100 min
Study: NCT04905667
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mg/kg, single dose, intravenous infusion, 90-100 min
Study: NCT00375076
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00722839
Drug: agatolimod sodium
Normalized name: AGATOLIMOD SODIUM
DrugBank: Agatolimod (DB15018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given subcutaneously
Study: NCT03755739
Drug: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
Study: NCT00280930
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193492
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00193492
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00860925
Drug: active clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
Study: NCT00830167
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Study: NCT04440696
Drug: Lanthanum Polystyrene Sulphonate Powder
Normalized name: lanthanum carbonate Oral Powder
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
Study: NCT04440696
Drug: Lanthanum Carbonate 500 MG
Normalized name: lanthanum carbonate 500 MG
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
Study: NCT00860925
Drug: active ASA
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
Study: NCT00860925
Drug: Clonidine Placebo
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
Study: NCT00424970
Drug: acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01985724
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
Study: NCT01985724
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Study: NCT01985724
Drug: Granulocyte-colony stimulating growth factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
Study: NCT03168035
Drug: NC-4016
Normalized name: 9-NC
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
Study: NCT01524016
Drug: 68Ga-DOTATATE
Normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
Study: NCT01580046
Drug: iodixanol
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection
Study: NCT01580046
Drug: iopromide
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
Study: NCT00003350
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04070079
Drug: Tenofovir Alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAF 25mg once daily orally, for 48 weeks
Study: NCT00361387
Drug: d-methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral dosing for 8 weeks then cross over to placebo in random order
Study: NCT01499160
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug is are to be taken orally. 2.5 mg once daily
Study: NCT04510168
Drug: 11C-ER176
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)
Study: NCT01499160
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
Study: NCT01499160
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug is to be taken orally. 5 mg once daily.
Study: NCT02101476
Drug: Percocet
Normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/650mg
Study: NCT04107727
Drug: Quizartinib
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.
Study: NCT02361736
Drug: Hydroxyethyl Starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
Study: NCT00564187
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A
Study: NCT00564187
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
Study: NCT01881737
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs.
Study: NCT02474654
Drug: Bupivicaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg
Study: NCT02474654
Drug: Epimorphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mcg
Study: NCT01711567
Drug: tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tenofovir 300 mg qd
Study: NCT01711567
Drug: entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: entecavir 0.5 mg qd
Study: NCT01186562
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg PO daily
Study: NCT04510168
Drug: Florbetaben
Normalized name: florbetaben
DrugBank: Florbetaben F-18 (DB09148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi
Study: NCT02725060
Drug: phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
Study: NCT02725060
Drug: isoproterenol
Normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
Study: NCT04107727
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.
Study: NCT00004216
Drug: cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004216
Drug: ceftriaxone sodium
Normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004216
Drug: ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004216
Drug: trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02566096
Drug: transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
Study: NCT04107727
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
Study: NCT03860948
Drug: Savolitinib Test Preparation
Normalized name: cranberry preparation
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (T): dry granulation savolitinib tablets.
Study: NCT01007019
Drug: YH4808 100mg (repeat dose)
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 100mg (repeat dose)
Study: NCT01007019
Drug: YH4808 200mg (repeat dose)
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 200mg (repeat dose)
Study: NCT01007019
Drug: YH4808 400 mg (repeat doses)
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH4808 400 mg (repeat doses)
Study: NCT01007019
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 volunteers will be administered Esomeprazole 40mg
Study: NCT03310619
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PD-L1
Study: NCT03310619
Drug: CC-122
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleiotropic Pathway Modifier
Study: NCT03310619
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib
Study: NCT03310619
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220
Study: NCT03310619
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Relatlimab
Study: NCT03310619
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab
Study: NCT03310619
Drug: CC-99282
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-99282
Study: NCT01160640
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ceftrixone 250mg IM single dose
Study: NCT01160640
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metronidazole 500 mg PO bid x 14 days
Study: NCT03269955
Drug: Fibrinogen/thrombin-coated collagen patch
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
Study: NCT03860948
Drug: Savolitinib Reference Preparation
Normalized name: cranberry preparation
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (R): wet granulation savolitinib tablets.
Study: NCT02538484
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase inhibitor
Study: NCT03796429
Drug: GS+Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years).
Study: NCT00002592
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00959621
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA 100 mg once daily per os
Study: NCT01224457
Drug: Phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
Study: NCT00959621
Drug: Klexane and ASA
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Klexane 40 mgx 1 sc and ASA 100 mg po
Study: NCT00536198
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
Study: NCT02922582
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00133679
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d